<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180307</url>
  </required_header>
  <id_info>
    <org_study_id>OTL-2016-OTL38-006</org_study_id>
    <nct_id>NCT03180307</nct_id>
  </id_info>
  <brief_title>OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</brief_title>
  <official_title>A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>On Target Laboratories, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynteractHCR</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>On Target Laboratories, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in&#xD;
      patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to&#xD;
      undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 3 study is to confirm the efficacy of OTL38 in combination with fluorescent light&#xD;
      to detect additional Folate Receptor-positive (FR+) ovarian cancer lesions not detected by&#xD;
      palpation and visualization under normal light in patients with FR+ ovarian cancer scheduled&#xD;
      to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer&#xD;
      surgery&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 26, 2018</start_date>
  <completion_date type="Actual">October 16, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy patient level</measure>
    <time_frame>30 days</time_frame>
    <description>• Proportion of patients with at least one evaluable FR+ ovarian cancer lesion confirmed by central pathology (Standard of truth) that was detected using the combination of OTL38 and fluorescent light but not under normal light or palpation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient false positive rate</measure>
    <time_frame>30 days</time_frame>
    <description>• False Positive Rate at the patient level (FPRp) will be a major secondary efficacy endpoint and is defined as the proportion of folate positive ovarian cancer patients in whom all lesions, without regard to evaluable lesion status, detected by fluorescent light only, are histologically negative</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>no fluorescent imaging</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patient injected with OTL38, but does not undergo fluorescent imaging</description>
  </arm_group>
  <arm_group>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient injected with OTL38 and undergoes near infrared imaging</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTL38</intervention_name>
    <description>0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes</description>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <arm_group_label>no fluorescent imaging</arm_group_label>
    <other_name>OTL38 for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>near infrared camera imaging system</intervention_name>
    <description>Infrared imaging used to excite OTL38 for fluorescence</description>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <other_name>Near IR imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparotomy</intervention_name>
    <description>primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery</description>
    <arm_group_label>near infrared imaging arm</arm_group_label>
    <arm_group_label>no fluorescent imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients 18 years of age and older&#xD;
&#xD;
          -  Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of&#xD;
             epithelial type), planned for primary surgical cytoreduction, interval debulking, or&#xD;
             have recurrent ovarian cancer surgery, and:&#xD;
&#xD;
               -  Who are scheduled to undergo laparotomy for the debulking surgery OR&#xD;
&#xD;
               -  Who are scheduled to undergo laparoscopy and pre-authorized to undergo laparotomy&#xD;
                  for the debulking surgery if cancer is detected on the laparoscopy&#xD;
&#xD;
          -  A negative serum pregnancy test at Screening followed by a negative urine pregnancy&#xD;
             test on the day of surgery or day of admission for female patients of childbearing&#xD;
             potential&#xD;
&#xD;
          -  Female patients of childbearing potential or less than 2 years postmenopausal agree to&#xD;
             use an acceptable form of contraception from the time of signing informed consent&#xD;
             until 30 days after study completion&#xD;
&#xD;
          -  Ability to understand the requirements of the study, provide written informed consent&#xD;
             for participation in the study and authorization of use and disclosure of protected&#xD;
             health information, and agree to abide by the study restrictions and to return for the&#xD;
             required assessments&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to OTL38&#xD;
&#xD;
          -  Known FR-negative ovarian cancer&#xD;
&#xD;
          -  Planned surgical debulking via laparoscopy or robotic surgery, with no intent of&#xD;
             laparotomy.&#xD;
&#xD;
          -  Patients with known ovarian cancer miliary disease determined preoperatively to be&#xD;
             inoperable.&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigators, could potentially&#xD;
             jeopardize the safety of the patient&#xD;
&#xD;
          -  History of anaphylactic reactions&#xD;
&#xD;
          -  History of allergy to any of the components of OTL38, including folic acid&#xD;
&#xD;
          -  Pregnancy or positive pregnancy test&#xD;
&#xD;
          -  Clinically significant abnormalities on electrocardiogram (ECG)&#xD;
&#xD;
          -  Presence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Impaired renal function defined as eGFR&lt; 50 mL/min/1.73m2&#xD;
&#xD;
          -  Impaired liver function defined as values &gt; 3x the upper limit of normal (ULN) for&#xD;
             alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase&#xD;
             (ALP), or total bilirubin.&#xD;
&#xD;
          -  Known Stage IV ovarian cancer with brain metastases&#xD;
&#xD;
          -  Received an investigational agent in another clinical trial within 30 days prior to&#xD;
             surgery&#xD;
&#xD;
          -  Known sensitivity to fluorescent light&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janos Tanyi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Mayo Clinic - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of CA at Irvine Chao Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institutes</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <state>South Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 14, 2021</submitted>
    <returned>November 11, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

